



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

**Correction to
Lancet Microbe 2021;
published online April 13.
[https://doi.org/10.1016/
S2666-5247\(21\)00082-3](https://doi.org/10.1016/S2666-5247(21)00082-3)**

Huang B, Dai L, Wang H, et al. Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2. *Lancet Microbe* 2021; published online April 13. [https://doi.org/10.1016/S2666-5247\(21\)00082-3](https://doi.org/10.1016/S2666-5247(21)00082-3)—The title page of the appendix accompanying this correspondence stated that the correspondence and appendix had been peer reviewed. This was incorrect. The cover page of the appendix has been corrected to reflect this as of April 27, 2021.

**Correction to
Lancet Microbe 2021;
published online April 20.
[https://doi.org/10.1016/
S2666-5247\(21\)00069-0](https://doi.org/10.1016/S2666-5247(21)00069-0)**

Olliaro P, Torreele E, Vaillant M. COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room. *Lancet Microbe* 2021; published online April 20. [https://doi.org/10.1016/S2666-5247\(21\)00069-0](https://doi.org/10.1016/S2666-5247(21)00069-0)—In this Comment, the relative risk reduction for the Gamaleya vaccine should have been 91%, and the numbers needed to vaccinate should have been 81 for the Moderna–NIH, 108 for the Gamaleya, and 119 for the Pfizer–BioNTech vaccines. These corrections have been made as of June 11, 2021.

**Correction to
Lancet Microbe 2021;
2: e331–41**

Gladstone RA, McNally A, Pöntinen AK, et al. Emergence and dissemination of antimicrobial resistance in *Escherichia coli* causing bloodstream infections in Norway in 2002–17: a nationwide, longitudinal, microbial population genomic study. *Lancet Microbe* 2021; 2: e331–41—In this Article, the data in the Estimated incidence per million population in 2017* (95% CI) and the Population size to incidence ratio in 2017 columns of the table have been updated. The appendix of this Article has been updated. The mean values reported in the Population size in 2017 (95% HPDI) column of the table have been replaced with median values. These corrections have been made as of June 29, 2021.



Published Online
April 27, 2021
[https://doi.org/10.1016/
S2666-5247\(21\)00116-6](https://doi.org/10.1016/S2666-5247(21)00116-6)

Published Online
June 11, 2021
[https://doi.org/10.1016/
S2666-5247\(21\)00152-X](https://doi.org/10.1016/S2666-5247(21)00152-X)